INTRODUCTION {#sec1-1}
============

Hyponatremia is an electrolyte disturbance in which the serum sodium concentration is lower than normal.\[[@ref1]\] It is one of the most common electrolyte abnormalities in hospitalized patients and may lead to complications such as prolonged hospitalization, seizures and increased mortality.\[[@ref2][@ref3]\] The first step in the treatment of hyponatremia is to determine the underlying cause by proper clinical assessment and also to establish the severity of hyponatremia by measuring serum and urinary sodium concentrations and osmolality.\[[@ref4]\] The treatment should be based on the severity of hyponatremia as the magnitude and rate of increase in serum sodium is critical. Under-correction of chronic hyponatremia may prolong the length of hospitalization and may fail to prevent life-threatening manifestations while sudden over-correction of sodium concentration may lead to osmotic myelinolysis.\[[@ref5]\]

The treatment of hyponatremia was controversial since it was found in the early 1980\'s that the rapid correction of hyponatremia can lead to central pontine myelinolysis and it was also reported that severe hyponatremia itself can lead to brain damage if not corrected rapidly.\[[@ref6][@ref7]\] The correction of serum sodium levels has a history even long before the measurements of serum sodium became available to clinicians. Clinicians understood that severe water intoxication can lead to cerebral edema and death can be prevented through reducing brain swelling by administration of hypertonic saline solution.\[[@ref8]\] Today, the treatment of hyponatremia has progressed a lot with a greater understanding of the human body and by developing accurate methods for the measurements of electrolyte levels. The mainstays of hyponatremia treatment were restricted free water intake and saline infusion.\[[@ref9][@ref10]\] These conventional approaches are effective, but the results are often unpredictable. The new studies have demonstrated the effectiveness of Vaptans (non-peptide arginine vasopressin receptor antagonists) in the treatment of hyponatremia.\[[@ref11][@ref12]\] Tolvaptan, the first orally acting vasopressin receptor antagonists induce aquaresis\[[@ref13]\] (formation of solute free urine) resulting in correction of osmolality and serum sodium concentration without the activation of the renin-angiotensin-aldosterone system or changes in blood pressure or renal function.\[[@ref14][@ref15]\] Furthermore current studies have proved that Tolvaptan can improve the treatment outcomes of hyponatremic patients suffering from acute and chronic heart failure, liver disease and end stage kidney disease.\[[@ref16]\]

METHODS {#sec1-2}
=======

The study was conducted in accordance with the ethical principles originated from the Declaration of Helsinki and also with the permission of Institutional ethics committee (The Erode College of Pharmacy Ethics Committee on Research on Human Subjects located at Erode, Tamil Nadu, India). Around 60 hospitalized patients having either euvolemic or hypervolemic hyponatremia and were not previously treated with Tolvaptan were randomly selected for the study during the period of February 2013-July 2013. The patients were randomized using 2:1 method and were either receiving oral Tolvaptan 15-30 mg once daily depending upon the severity of hyponatremia or intravenous infusion of 3% hypertonic saline solution based on their body weight and baseline serum sodium concentration in order to correct the plasma sodium deficiency. The parameters for inclusion of subjects into the study were hyponatremic hospitalized patients aged 25-70 years who were either being treated with oral Tolvaptan or 3% hypertonic saline solution. Although the exclusion parameter were patients with hypovolemic hyponatremia, patients who were not willing to stay in hospital, patients treated with either of the study drugs 6 months prior to the onset of study, patients with severe renal impairment and patients who were hypersensitive to Tolvaptan or similar class of drugs. The electrolyte levels of the patients were closely monitored in order to determine if there are any fluctuations. The initial serum sodium concentration before the administration of the study drugs were compared with the values obtained 24 h and 48 h after the administration of either oral Tolvaptan or 3% hypertonic saline solution. The primary end point of the study was to determine the acute effect of Tolvaptan and 3% hypertonic saline solution on serum sodium concentration. Serum Sodium concentration at 24 h and 48 h after the administration of the study drug was determined and compared against the baseline serum sodium concentration. Data were analyzed using GraphPad Prism (Inc. 7825 Fay Avenue, Suite 230 La Jolla, CA 92037 USA), Version 6.0. The results were presented using absolute percentages. Analysis was performed using Student\'s paired *t*-test One-way analysis of variance.

RESULTS {#sec1-3}
=======

Out of the 60 enrolled patients, Tolvaptan 15-30 mg was administered to 37 patients depending upon the severity of hyponatremia. Serum sodium concentration was significantly increased at 24 h while the effect persisted at 48 h in this group of patients. Similarly, serum sodium concentration was found to be increased significantly at both 24 h and 48 h when compared with the baseline values in 23 patients who received 3% hypertonic saline solution \[[Table 1](#T1){ref-type="table"}\].

###### 

The effect of oral Tolvaptan and 3% hypertonic saline solution on serum sodium concentration in hyponatremic patients

![](JRPP-3-34-g001)

On evaluation of the efficacy of both oral Tolvaptan and 3% hypertonic saline solution on hyponatremic hospitalized patients, it was concluded that both drugs had significant effects on serum sodium concentration. Statistical analysis proved that 3% saline solution had a greater efficacy in increasing the serum sodium concentration than Tolvaptan on the study population \[*P* \< 0.001; [Table 1](#T1){ref-type="table"}\] at both 24 h and 48 h analysis

DISCUSSION {#sec1-4}
==========

SALT Investigators studied the clinical efficacy of Tolvaptan in patients with hyponatremia due to multiple disorders including syndrome of inappropriate antidiuretic hormone secretions,\[[@ref17]\] chronic heart failure or cirrhosis.\[[@ref18]\] Studies of ascending levels of Tolvaptan (SALT-1 and SALT-2) enrolled 205 and 243 patients, respectively. The patients were given daily oral doses of placebo or Tolvaptan 15 mg with titration to 30 and 60 mg, 4 times a day, with a 7 days follow-up visit after the end of the study. Primary end points were changes in sodium from baseline to day 4 and day 30 of treatment. SALT-1 patients who received Tolvaptan had a daily area under the curve change in serum sodium by day 4 of 3.62 ± 2.68 mEq/L when compared with 0.25 ± 2.08 mEq/L in the placebo group (*P* \< 0.0001). At day 30, this averaged 1.66 ± 3.59 mEq/L for placebo and 6.22 ± 4.10 mEq/L for Tolvaptan (*P* \< 0.0001). SALT-2 showed the similar results; so in both studies, serum sodium improved in Tolvaptan treated patients. Tolvaptan was fond to be superior to placebo in raising and maintaining serum sodium concentration; also, Tolvaptan treated patients required less fluid restrictions

Hyponatremia is one of the most common electrolyte disturbances occurring in hospitalized patients and may result in many serious discomforts and adverse events including prolongation of hospitalization and even death. The treatment options of hyponatremia changed dramatically after the understanding of the molecular level of the condition which led to the discovery of a new class of drugs, arginine vasopressin-2 (AVP) receptor antagonists. Tolvaptan, the first orally acting AVP receptor antagonist is now used widely for the correction of hyponatremia and associated conditions.
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